First results from the Swedish National Pancreatic and Periampullary Cancer Registry
| Autor: | Victoria Formichov, Bodil Andersson, Svein Olav Bratlie, Christophe Ansorge, Ralf Segersvärd, Britt Marie Karlsson, Mikael Öhman, Bobby Tingstedt, Thomas Gasslander, Claes Jönsson |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Ampulla of Vater
medicine.medical_specialty Time Factors Pancreatic ductal adenocarcinoma Common Bile Duct Neoplasms MEDLINE 030230 surgery Risk Assessment Pancreaticoduodenectomy Resection 03 medical and health sciences 0302 clinical medicine Duodenal Neoplasms Risk Factors Pancreatic cancer Periampullary cancer Humans Medicine Registries Practice Patterns Physicians' Quality Indicators Health Care Sweden Hepatology business.industry General surgery Gastroenterology Cancer medicine.disease Quality Improvement people.cause_of_death Pancreatic Neoplasms Treatment Outcome 030220 oncology & carcinogenesis National registry business Risk assessment people |
| Zdroj: | HPB. 21:34-42 |
| ISSN: | 1365-182X |
| DOI: | 10.1016/j.hpb.2018.06.1811 |
| Popis: | Background Despite improvements in therapy regimens over the past decades, overall survival rates for pancreatic and periampullary cancer are poor. Specific cancer registries are set up in various nations to regional differences and to enable larger prospective trials. The aim of this study was to describe the Swedish register, including possibilities to improve diagnostic work-ups, treatment, and follow-up by means of the register. Methods Since 2010, all patients with pancreatic and periampullary cancer (including also patients who have undergone pancreatic surgery due to premalignant or benign lesions) have been registered in the Swedish National Periampullary and Pancreatic Cancer registry. Results In total 9887 patients are listed in the registry; 8207 of those have malignant periampullary cancer. Approximately one-third (3282 patients) have had resections performed, including benign/premalignant resections. 30-day and 90-day mortality after pancreatoduodenectomy is 1.5% and 3.5%, respectively. The overall 3-year survival for resected pancreatic ductal adenocarcinoma is 35%. Regional variations decreased over the studied period, but still exist. Conclusion Results from the Swedish National Registry are satisfactory and comparable to international standards. Trends over time show increasing resection rates and some improved results. Better collaboration and openness within pancreatic surgeons is an important side effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|